Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

Keywords

MedicinePembrolizumabNeoadjuvant therapyAdjuvantOncologyImmune systemImmunotherapyBlockadeAdjuvant therapyPopulationInternal medicineImmune checkpointChemotherapyImmunologyCancerReceptorBreast cancer

Affiliated Institutions

Related Publications

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

Matthew M. Gubin , Xiuli Zhang , Heiko Schuster +24 more

The immune system influences the fate of developing cancers by not only functioning as a tumour promoter that facilitates cellular transformation, promotes tumour growth and scu...

2014 Nature 1936 citations

Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

Evan J. Lipson , William H. Sharfman , Charles G. Drake +10 more

Abstract Purpose: Results from the first-in-human phase I trial of the anti–programmed death-1 (PD-1) antibody BMS-936558 in patients with treatment-refractory solid tumors, inc...

2012 Clinical Cancer Research 529 citations

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Julie R. Brahmer , Charles G. Drake , Ira Wollner +17 more

Purpose Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, may suppress antitumor immunity. This phase I study sought to determine the safety and ...

2010 Journal of Clinical Oncology 2881 citations

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

Matthew D. Hellmann , Tavi Nathanson , Hira Rizvi +29 more

Combination immune checkpoint blockade has demonstrated promising benefit in lung cancer, but predictors of response to combination therapy are unknown. Using whole-exome sequen...

2018 Cancer Cell 1147 citations

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés , David W. Cescon , Hope S. Rugo +97 more

Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer. We aimed to examine whether the add...

2020 The Lancet 1658 citations

Publication Info

Year: 2019
Type: article
Volume: 25
Issue: 3
Pages: 477-486
Citations: 1310
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1310

OpenAlex

Cite This

APA Style

                            
                                
                                    Timothy F. Cloughesy, 
                                
                                    Aaron Mochizuki, 
                                
                                    Joey Orpilla
                                
                                et al.
                            
                            (2019). 
                            Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. 
                            Nature Medicine
                            , 25
                            (3)
                            , 477-486.
                            https://doi.org/10.1038/s41591-018-0337-7
                        

Identifiers

DOI: 10.1038/s41591-018-0337-7